CalciMedica, Inc. (CALC) Income Statement
CALC 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCALC revenue and net income
CALC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CALC quarterly EPS vs estimates
CalciMedica beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.75).
CALC income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $46,000 | $58,000 | $58,000 | $52,000 | $519,000 | $395,000 | $303,000 | $175,000 |
| Gross profit | −$46,000 | −$58,000 | −$58,000 | −$52,000 | −$519,000 | −$395,000 | −$303,000 | −$175,000 |
| Research & development | $15.2M | $14.5M | $15.9M | $8.3M | $18.9M | $21.0M | $30.6M | $23.0M |
| Sales, general & admin | $7.9M | $9.7M | $22.2M | $5.8M | $17.0M | $8.9M | $6.9M | $5.6M |
| Total operating expenses | $23.1M | $24.2M | $38.1M | $14.2M | $35.9M | $29.8M | $37.2M | $28.6M |
| Operating income | −$23.1M | −$24.2M | −$38.1M | −$14.2M | −$35.9M | −$29.8M | −$37.5M | −$28.6M |
| Interest income | $713,000 | $1.0M | — | $575,000 | $126,000 | $143,000 | $393,000 | — |
| Interest expense | $1.4M | $0 | $110,000 | $132,000 | $126,000 | $143,000 | — | — |
| Income before taxes | −$29.6M | −$13.7M | −$34.4M | −$7.8M | −$35.8M | −$27.5M | −$37.0M | −$28.4M |
| Income taxes | — | — | −$109,895 | $2.4M | −$2.0M | −$538,000 | −$393,000 | $13,859 |
| Net income | −$29.6M | −$13.7M | −$34.4M | −$7.8M | −$35.8M | −$27.5M | −$37.0M | −$28.4M |
| EBITDA | −$28.1M | −$13.6M | −$34.2M | −$7.6M | −$35.4M | −$29.4M | −$36.7M | −$28.2M |
| EPS (diluted) | −$4.73 | −$2.07 | −$5.57 | −$24.92 | −$23.66 | −$4.68 | −$179.27 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $60,000 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $7,000 | $5,000 | — | — | $15,000 | $14,000 | $15,000 | $15,000 | $15,000 | — | $12,000 |
| Gross profit | — | −$7,000 | −$5,000 | — | — | −$15,000 | −$14,000 | −$15,000 | −$15,000 | −$15,000 | — | −$12,000 |
| Research & development | $2.1M | $3.5M | $3.1M | $3.9M | $4.1M | $4.2M | $3.8M | $3.5M | $4.2M | $2.9M | $2.8M | $2.8M |
| Sales, general & admin | $1.9M | $2.1M | $1.3M | $1.8M | $2.6M | $2.3M | $2.3M | $2.2M | $2.4M | $2.8M | $1.5M | $2.1M |
| Total operating expenses | $4.0M | $5.6M | $4.4M | $5.6M | $6.6M | $6.5M | $6.2M | $5.7M | $6.5M | $5.8M | $4.3M | $4.8M |
| Operating income | −$4.0M | −$5.6M | −$4.4M | −$5.6M | −$6.6M | −$6.5M | −$6.2M | −$5.7M | −$6.5M | −$5.8M | −$4.3M | −$4.8M |
| Interest income | $54,000 | $106,000 | $151,000 | $140,000 | $220,000 | $202,000 | — | $218,000 | $275,000 | — | — | — |
| Interest expense | $325,000 | $319,000 | $325,000 | $326,000 | $324,000 | $447,000 | — | $0 | $0 | $0 | — | — |
| Income before taxes | −$7.7M | $5.0M | −$10.8M | −$7.8M | −$6.0M | −$5.0M | −$4.3M | −$5.6M | −$4.0M | $130,000 | −$4.1M | −$4.6M |
| Income taxes | — | — | — | — | — | — | $15,000 | — | — | −$15,000 | $3.9M | $51,586 |
| Net income | −$7.7M | $5.0M | −$10.8M | −$7.8M | −$6.0M | −$5.0M | −$4.3M | −$5.6M | −$4.0M | $130,000 | −$4.1M | −$4.6M |
| EBITDA | −$7.3M | $5.3M | −$10.4M | −$7.5M | −$5.6M | −$4.6M | −$4.2M | −$5.6M | −$3.9M | $145,000 | −$472,000 | −$4.6M |
| EPS (diluted) | −$0.45 | $0.30 | −$3.45 | −$0.52 | −$0.40 | −$0.36 | −$1.22 | −$0.50 | −$0.36 | $0.01 | −$0.23 | −$0.82 |
| Gross margin | — | — | — | — | — | — | −23.3% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −10,286.7% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −7,096.7% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CALC's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CALC financial results
CalciMedica reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $29.6 million. Diluted earnings per share came to −$4.73.
See the CALC stock overview for the latest quote and news, or the CALC chart for price history and technical indicators.
CALC income statement FAQ
Does CalciMedica have revenue?
CalciMedica reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is CalciMedica profitable?
No. CalciMedica reported a net loss of $29.6 million in fiscal 2025.
How much does CalciMedica spend on research and development?
CalciMedica spent $15.2 million on research and development in fiscal 2025.
What are CalciMedica's earnings per share?
CalciMedica earned $-4.73 per diluted share in fiscal 2025, compared with $-2.07 a year earlier.
When will CalciMedica report its next earnings?
CalciMedica is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does CalciMedica's fiscal year end?
CalciMedica's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.